nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—neck—head and neck cancer	0.00281	0.12	CbGeAlD
Everolimus—FKBP1A—neck—head and neck cancer	0.00253	0.108	CbGeAlD
Everolimus—MTOR—connective tissue—head and neck cancer	0.00202	0.0858	CbGeAlD
Everolimus—MTOR—epithelium—head and neck cancer	0.00191	0.0814	CbGeAlD
Everolimus—Haemoglobin—Vinblastine—head and neck cancer	0.00189	0.00357	CcSEcCtD
Everolimus—Haemorrhage—Vinblastine—head and neck cancer	0.00188	0.00356	CcSEcCtD
Everolimus—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00188	0.00355	CcSEcCtD
Everolimus—Hypoaesthesia—Vinblastine—head and neck cancer	0.00187	0.00354	CcSEcCtD
Everolimus—Pharyngitis—Vinblastine—head and neck cancer	0.00187	0.00353	CcSEcCtD
Everolimus—Stomatitis—Hydroxyurea—head and neck cancer	0.00187	0.00352	CcSEcCtD
Everolimus—Inflammation—Docetaxel—head and neck cancer	0.00183	0.00346	CcSEcCtD
Everolimus—Cardiac failure—Fluorouracil—head and neck cancer	0.00183	0.00346	CcSEcCtD
Everolimus—Lethargy—Fluorouracil—head and neck cancer	0.00182	0.00344	CcSEcCtD
Everolimus—FKBP1A—connective tissue—head and neck cancer	0.00181	0.0772	CbGeAlD
Everolimus—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00181	0.00342	CcSEcCtD
Everolimus—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00178	0.00336	CcSEcCtD
Everolimus—Hepatocellular injury—Docetaxel—head and neck cancer	0.00178	0.00336	CcSEcCtD
Everolimus—Pulmonary embolism—Docetaxel—head and neck cancer	0.00178	0.00336	CcSEcCtD
Everolimus—Haemoglobin—Hydroxyurea—head and neck cancer	0.00173	0.00326	CcSEcCtD
Everolimus—FKBP1A—epithelium—head and neck cancer	0.00172	0.0732	CbGeAlD
Everolimus—Haemorrhage—Hydroxyurea—head and neck cancer	0.00172	0.00324	CcSEcCtD
Everolimus—Hallucination—Hydroxyurea—head and neck cancer	0.00171	0.00323	CcSEcCtD
Everolimus—Irritability—Fluorouracil—head and neck cancer	0.00171	0.00322	CcSEcCtD
Everolimus—Cardiac arrest—Fluorouracil—head and neck cancer	0.0017	0.00321	CcSEcCtD
Everolimus—Candida infection—Docetaxel—head and neck cancer	0.0017	0.0032	CcSEcCtD
Everolimus—Skin exfoliation—Docetaxel—head and neck cancer	0.0017	0.0032	CcSEcCtD
Everolimus—Fluid retention—Docetaxel—head and neck cancer	0.00169	0.00319	CcSEcCtD
Everolimus—Alopecia—Vinblastine—head and neck cancer	0.00166	0.00314	CcSEcCtD
Everolimus—Dry skin—Fluorouracil—head and neck cancer	0.00164	0.00309	CcSEcCtD
Everolimus—Neoplasm—Docetaxel—head and neck cancer	0.00161	0.00303	CcSEcCtD
Everolimus—Nasopharyngitis—Fluorouracil—head and neck cancer	0.0016	0.00302	CcSEcCtD
Everolimus—Pulmonary oedema—Docetaxel—head and neck cancer	0.00158	0.00299	CcSEcCtD
Everolimus—Muscular weakness—Fluorouracil—head and neck cancer	0.00158	0.00298	CcSEcCtD
Everolimus—Angiopathy—Hydroxyurea—head and neck cancer	0.00156	0.00294	CcSEcCtD
Everolimus—Dysphagia—Fluorouracil—head and neck cancer	0.00154	0.00292	CcSEcCtD
Everolimus—Sepsis—Docetaxel—head and neck cancer	0.00154	0.00291	CcSEcCtD
Everolimus—Chills—Hydroxyurea—head and neck cancer	0.00154	0.00291	CcSEcCtD
Everolimus—FKBP1A—trachea—head and neck cancer	0.00152	0.0648	CbGeAlD
Everolimus—Ill-defined disorder—Vinblastine—head and neck cancer	0.00152	0.00287	CcSEcCtD
Everolimus—Alopecia—Hydroxyurea—head and neck cancer	0.00152	0.00287	CcSEcCtD
Everolimus—Anaemia—Vinblastine—head and neck cancer	0.00152	0.00286	CcSEcCtD
Everolimus—Angina pectoris—Fluorouracil—head and neck cancer	0.0015	0.00284	CcSEcCtD
Everolimus—Erythema—Hydroxyurea—head and neck cancer	0.0015	0.00282	CcSEcCtD
Everolimus—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00148	0.0028	CcSEcCtD
Everolimus—Malaise—Vinblastine—head and neck cancer	0.00148	0.00279	CcSEcCtD
Everolimus—MTOR—lymphoid tissue—head and neck cancer	0.00147	0.0627	CbGeAlD
Everolimus—Leukopenia—Vinblastine—head and neck cancer	0.00147	0.00277	CcSEcCtD
Everolimus—Pancytopenia—Fluorouracil—head and neck cancer	0.00147	0.00277	CcSEcCtD
Everolimus—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00144	0.00271	CcSEcCtD
Everolimus—Hepatic failure—Docetaxel—head and neck cancer	0.00144	0.00271	CcSEcCtD
Everolimus—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00142	0.00269	CcSEcCtD
Everolimus—Convulsion—Vinblastine—head and neck cancer	0.00142	0.00268	CcSEcCtD
Everolimus—Hypertension—Vinblastine—head and neck cancer	0.00142	0.00267	CcSEcCtD
Everolimus—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00139	0.00262	CcSEcCtD
Everolimus—Pneumonia—Fluorouracil—head and neck cancer	0.00139	0.00262	CcSEcCtD
Everolimus—Anaemia—Hydroxyurea—head and neck cancer	0.00138	0.00261	CcSEcCtD
Everolimus—Discomfort—Vinblastine—head and neck cancer	0.00138	0.0026	CcSEcCtD
Everolimus—Hot flush—Docetaxel—head and neck cancer	0.00138	0.0026	CcSEcCtD
Everolimus—Infestation NOS—Fluorouracil—head and neck cancer	0.00138	0.0026	CcSEcCtD
Everolimus—Infestation—Fluorouracil—head and neck cancer	0.00138	0.0026	CcSEcCtD
Everolimus—Menopausal symptoms—Docetaxel—head and neck cancer	0.00137	0.00258	CcSEcCtD
Everolimus—Atrial fibrillation—Docetaxel—head and neck cancer	0.00136	0.00257	CcSEcCtD
Everolimus—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00136	0.00256	CcSEcCtD
Everolimus—Renal impairment—Docetaxel—head and neck cancer	0.00136	0.00256	CcSEcCtD
Everolimus—Myocardial infarction—Fluorouracil—head and neck cancer	0.00135	0.00255	CcSEcCtD
Everolimus—Malaise—Hydroxyurea—head and neck cancer	0.00135	0.00255	CcSEcCtD
Everolimus—Stomatitis—Fluorouracil—head and neck cancer	0.00134	0.00253	CcSEcCtD
Everolimus—MTOR—thyroid gland—head and neck cancer	0.00134	0.057	CbGeAlD
Everolimus—Urinary tract infection—Fluorouracil—head and neck cancer	0.00134	0.00253	CcSEcCtD
Everolimus—Conjunctivitis—Fluorouracil—head and neck cancer	0.00134	0.00253	CcSEcCtD
Everolimus—Leukopenia—Hydroxyurea—head and neck cancer	0.00134	0.00253	CcSEcCtD
Everolimus—FKBP1A—lymphoid tissue—head and neck cancer	0.00133	0.0564	CbGeAlD
Everolimus—Cardiac failure—Docetaxel—head and neck cancer	0.00132	0.0025	CcSEcCtD
Everolimus—Lethargy—Docetaxel—head and neck cancer	0.00132	0.00249	CcSEcCtD
Everolimus—Thrombocytopenia—Vinblastine—head and neck cancer	0.00131	0.00247	CcSEcCtD
Everolimus—Epistaxis—Fluorouracil—head and neck cancer	0.0013	0.00245	CcSEcCtD
Everolimus—Convulsion—Hydroxyurea—head and neck cancer	0.0013	0.00245	CcSEcCtD
Everolimus—Hyponatraemia—Docetaxel—head and neck cancer	0.0013	0.00245	CcSEcCtD
Everolimus—Sinusitis—Fluorouracil—head and neck cancer	0.00129	0.00244	CcSEcCtD
Everolimus—Pain in extremity—Docetaxel—head and neck cancer	0.00129	0.00244	CcSEcCtD
Everolimus—Anorexia—Vinblastine—head and neck cancer	0.00128	0.00241	CcSEcCtD
Everolimus—Migraine—Docetaxel—head and neck cancer	0.00127	0.0024	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00126	0.00239	CcSEcCtD
Everolimus—Discomfort—Hydroxyurea—head and neck cancer	0.00126	0.00237	CcSEcCtD
Everolimus—Haemoglobin—Fluorouracil—head and neck cancer	0.00124	0.00235	CcSEcCtD
Everolimus—Rhinitis—Fluorouracil—head and neck cancer	0.00124	0.00234	CcSEcCtD
Everolimus—Haemorrhage—Fluorouracil—head and neck cancer	0.00124	0.00233	CcSEcCtD
Everolimus—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00123	0.00232	CcSEcCtD
Everolimus—Pharyngitis—Fluorouracil—head and neck cancer	0.00123	0.00232	CcSEcCtD
Everolimus—Oedema—Hydroxyurea—head and neck cancer	0.00122	0.0023	CcSEcCtD
Everolimus—Infection—Hydroxyurea—head and neck cancer	0.00121	0.00229	CcSEcCtD
Everolimus—FKBP1A—thyroid gland—head and neck cancer	0.0012	0.0512	CbGeAlD
Everolimus—Paraesthesia—Vinblastine—head and neck cancer	0.0012	0.00227	CcSEcCtD
Everolimus—Dehydration—Docetaxel—head and neck cancer	0.0012	0.00226	CcSEcCtD
Everolimus—Nervous system disorder—Hydroxyurea—head and neck cancer	0.0012	0.00226	CcSEcCtD
Everolimus—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.0012	0.00226	CcSEcCtD
Everolimus—Liver function test abnormal—Docetaxel—head and neck cancer	0.00119	0.00225	CcSEcCtD
Everolimus—MTOR—head—head and neck cancer	0.00119	0.0505	CbGeAlD
Everolimus—Skin disorder—Hydroxyurea—head and neck cancer	0.00119	0.00224	CcSEcCtD
Everolimus—Dry skin—Docetaxel—head and neck cancer	0.00118	0.00223	CcSEcCtD
Everolimus—Abdominal pain upper—Docetaxel—head and neck cancer	0.00118	0.00222	CcSEcCtD
Everolimus—Breast disorder—Docetaxel—head and neck cancer	0.00117	0.0022	CcSEcCtD
Everolimus—Anorexia—Hydroxyurea—head and neck cancer	0.00116	0.0022	CcSEcCtD
Everolimus—Decreased appetite—Vinblastine—head and neck cancer	0.00116	0.0022	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00116	0.00219	CcSEcCtD
Everolimus—Nasopharyngitis—Docetaxel—head and neck cancer	0.00115	0.00218	CcSEcCtD
Everolimus—Pain—Vinblastine—head and neck cancer	0.00114	0.00216	CcSEcCtD
Everolimus—Constipation—Vinblastine—head and neck cancer	0.00114	0.00216	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00114	0.00215	CcSEcCtD
Everolimus—Dysphagia—Docetaxel—head and neck cancer	0.00112	0.0021	CcSEcCtD
Everolimus—Feeling abnormal—Vinblastine—head and neck cancer	0.0011	0.00208	CcSEcCtD
Everolimus—Bronchospasm—Docetaxel—head and neck cancer	0.0011	0.00207	CcSEcCtD
Everolimus—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00109	0.00207	CcSEcCtD
Everolimus—Alopecia—Fluorouracil—head and neck cancer	0.00109	0.00206	CcSEcCtD
Everolimus—Dyspnoea—Hydroxyurea—head and neck cancer	0.00109	0.00205	CcSEcCtD
Everolimus—Angina pectoris—Docetaxel—head and neck cancer	0.00109	0.00205	CcSEcCtD
Everolimus—Somnolence—Hydroxyurea—head and neck cancer	0.00109	0.00205	CcSEcCtD
Everolimus—Erythema—Fluorouracil—head and neck cancer	0.00108	0.00203	CcSEcCtD
Everolimus—Dyspepsia—Hydroxyurea—head and neck cancer	0.00107	0.00203	CcSEcCtD
Everolimus—FKBP1A—head—head and neck cancer	0.00107	0.0455	CbGeAlD
Everolimus—Decreased appetite—Hydroxyurea—head and neck cancer	0.00106	0.002	CcSEcCtD
Everolimus—Pancytopenia—Docetaxel—head and neck cancer	0.00106	0.002	CcSEcCtD
Everolimus—Abdominal pain—Vinblastine—head and neck cancer	0.00106	0.002	CcSEcCtD
Everolimus—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00105	0.00199	CcSEcCtD
Everolimus—Fatigue—Hydroxyurea—head and neck cancer	0.00105	0.00199	CcSEcCtD
Everolimus—Constipation—Hydroxyurea—head and neck cancer	0.00104	0.00197	CcSEcCtD
Everolimus—Pain—Hydroxyurea—head and neck cancer	0.00104	0.00197	CcSEcCtD
Everolimus—Neutropenia—Docetaxel—head and neck cancer	0.00104	0.00197	CcSEcCtD
Everolimus—Vision blurred—Fluorouracil—head and neck cancer	0.00101	0.00191	CcSEcCtD
Everolimus—Weight decreased—Docetaxel—head and neck cancer	0.00101	0.0019	CcSEcCtD
Everolimus—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00101	0.0019	CcSEcCtD
Everolimus—Pneumonia—Docetaxel—head and neck cancer	0.001	0.00189	CcSEcCtD
Everolimus—Anaemia—Fluorouracil—head and neck cancer	0.000995	0.00188	CcSEcCtD
Everolimus—Infestation NOS—Docetaxel—head and neck cancer	0.000994	0.00188	CcSEcCtD
Everolimus—Infestation—Docetaxel—head and neck cancer	0.000994	0.00188	CcSEcCtD
Everolimus—Hypersensitivity—Vinblastine—head and neck cancer	0.000986	0.00186	CcSEcCtD
Everolimus—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00098	0.00185	CcSEcCtD
Everolimus—Renal failure—Docetaxel—head and neck cancer	0.000977	0.00184	CcSEcCtD
Everolimus—Myocardial infarction—Docetaxel—head and neck cancer	0.000975	0.00184	CcSEcCtD
Everolimus—Jaundice—Docetaxel—head and neck cancer	0.000969	0.00183	CcSEcCtD
Everolimus—Stomatitis—Docetaxel—head and neck cancer	0.000969	0.00183	CcSEcCtD
Everolimus—Conjunctivitis—Docetaxel—head and neck cancer	0.000966	0.00182	CcSEcCtD
Everolimus—Body temperature increased—Hydroxyurea—head and neck cancer	0.000965	0.00182	CcSEcCtD
Everolimus—Leukopenia—Fluorouracil—head and neck cancer	0.000964	0.00182	CcSEcCtD
Everolimus—Asthenia—Vinblastine—head and neck cancer	0.00096	0.00181	CcSEcCtD
Everolimus—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00094	0.00177	CcSEcCtD
Everolimus—Epistaxis—Docetaxel—head and neck cancer	0.000938	0.00177	CcSEcCtD
Everolimus—Convulsion—Fluorouracil—head and neck cancer	0.000933	0.00176	CcSEcCtD
Everolimus—Chest pain—Fluorouracil—head and neck cancer	0.000916	0.00173	CcSEcCtD
Everolimus—Myalgia—Fluorouracil—head and neck cancer	0.000916	0.00173	CcSEcCtD
Everolimus—Diarrhoea—Vinblastine—head and neck cancer	0.000916	0.00173	CcSEcCtD
Everolimus—Discomfort—Fluorouracil—head and neck cancer	0.000905	0.00171	CcSEcCtD
Everolimus—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000899	0.0017	CcSEcCtD
Everolimus—Haemoglobin—Docetaxel—head and neck cancer	0.000897	0.00169	CcSEcCtD
Everolimus—Rhinitis—Docetaxel—head and neck cancer	0.000895	0.00169	CcSEcCtD
Everolimus—Haemorrhage—Docetaxel—head and neck cancer	0.000892	0.00168	CcSEcCtD
Everolimus—Hepatitis—Docetaxel—head and neck cancer	0.000892	0.00168	CcSEcCtD
Everolimus—Hypoaesthesia—Docetaxel—head and neck cancer	0.000888	0.00168	CcSEcCtD
Everolimus—Pharyngitis—Docetaxel—head and neck cancer	0.000886	0.00167	CcSEcCtD
Everolimus—Dizziness—Vinblastine—head and neck cancer	0.000885	0.00167	CcSEcCtD
Everolimus—Urinary tract disorder—Docetaxel—head and neck cancer	0.000881	0.00166	CcSEcCtD
Everolimus—Oedema peripheral—Docetaxel—head and neck cancer	0.000879	0.00166	CcSEcCtD
Everolimus—Oedema—Fluorouracil—head and neck cancer	0.000879	0.00166	CcSEcCtD
Everolimus—Connective tissue disorder—Docetaxel—head and neck cancer	0.000877	0.00166	CcSEcCtD
Everolimus—Asthenia—Hydroxyurea—head and neck cancer	0.000876	0.00165	CcSEcCtD
Everolimus—Urethral disorder—Docetaxel—head and neck cancer	0.000875	0.00165	CcSEcCtD
Everolimus—Infection—Fluorouracil—head and neck cancer	0.000873	0.00165	CcSEcCtD
Everolimus—Nervous system disorder—Fluorouracil—head and neck cancer	0.000862	0.00163	CcSEcCtD
Everolimus—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00086	0.00162	CcSEcCtD
Everolimus—Tachycardia—Fluorouracil—head and neck cancer	0.000857	0.00162	CcSEcCtD
Everolimus—Vomiting—Vinblastine—head and neck cancer	0.000851	0.00161	CcSEcCtD
Everolimus—Headache—Vinblastine—head and neck cancer	0.000838	0.00158	CcSEcCtD
Everolimus—Anorexia—Fluorouracil—head and neck cancer	0.000837	0.00158	CcSEcCtD
Everolimus—Diarrhoea—Hydroxyurea—head and neck cancer	0.000835	0.00158	CcSEcCtD
Everolimus—Eye disorder—Docetaxel—head and neck cancer	0.000834	0.00157	CcSEcCtD
Everolimus—MTOR—lymph node—head and neck cancer	0.000832	0.0354	CbGeAlD
Everolimus—Flushing—Docetaxel—head and neck cancer	0.000828	0.00156	CcSEcCtD
Everolimus—Cardiac disorder—Docetaxel—head and neck cancer	0.000828	0.00156	CcSEcCtD
Everolimus—Hypotension—Fluorouracil—head and neck cancer	0.000821	0.00155	CcSEcCtD
Everolimus—Angiopathy—Docetaxel—head and neck cancer	0.00081	0.00153	CcSEcCtD
Everolimus—Dizziness—Hydroxyurea—head and neck cancer	0.000807	0.00152	CcSEcCtD
Everolimus—Immune system disorder—Docetaxel—head and neck cancer	0.000806	0.00152	CcSEcCtD
Everolimus—Mediastinal disorder—Docetaxel—head and neck cancer	0.000804	0.00152	CcSEcCtD
Everolimus—Chills—Docetaxel—head and neck cancer	0.000801	0.00151	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.0008	0.00151	CcSEcCtD
Everolimus—Nausea—Vinblastine—head and neck cancer	0.000795	0.0015	CcSEcCtD
Everolimus—Insomnia—Fluorouracil—head and neck cancer	0.000795	0.0015	CcSEcCtD
Everolimus—Paraesthesia—Fluorouracil—head and neck cancer	0.000789	0.00149	CcSEcCtD
Everolimus—Alopecia—Docetaxel—head and neck cancer	0.000789	0.00149	CcSEcCtD
Everolimus—Dyspnoea—Fluorouracil—head and neck cancer	0.000783	0.00148	CcSEcCtD
Everolimus—Mental disorder—Docetaxel—head and neck cancer	0.000782	0.00148	CcSEcCtD
Everolimus—Somnolence—Fluorouracil—head and neck cancer	0.000781	0.00147	CcSEcCtD
Everolimus—Erythema—Docetaxel—head and neck cancer	0.000777	0.00147	CcSEcCtD
Everolimus—Malnutrition—Docetaxel—head and neck cancer	0.000777	0.00147	CcSEcCtD
Everolimus—Vomiting—Hydroxyurea—head and neck cancer	0.000776	0.00146	CcSEcCtD
Everolimus—Dyspepsia—Fluorouracil—head and neck cancer	0.000773	0.00146	CcSEcCtD
Everolimus—Rash—Hydroxyurea—head and neck cancer	0.00077	0.00145	CcSEcCtD
Everolimus—Dermatitis—Hydroxyurea—head and neck cancer	0.000769	0.00145	CcSEcCtD
Everolimus—Headache—Hydroxyurea—head and neck cancer	0.000765	0.00144	CcSEcCtD
Everolimus—Decreased appetite—Fluorouracil—head and neck cancer	0.000764	0.00144	CcSEcCtD
Everolimus—Dysgeusia—Docetaxel—head and neck cancer	0.000761	0.00144	CcSEcCtD
Everolimus—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000758	0.00143	CcSEcCtD
Everolimus—Back pain—Docetaxel—head and neck cancer	0.000752	0.00142	CcSEcCtD
Everolimus—Pain—Fluorouracil—head and neck cancer	0.000751	0.00142	CcSEcCtD
Everolimus—FKBP1A—lymph node—head and neck cancer	0.000748	0.0318	CbGeAlD
Everolimus—Muscle spasms—Docetaxel—head and neck cancer	0.000747	0.00141	CcSEcCtD
Everolimus—Nausea—Hydroxyurea—head and neck cancer	0.000725	0.00137	CcSEcCtD
Everolimus—Feeling abnormal—Fluorouracil—head and neck cancer	0.000724	0.00137	CcSEcCtD
Everolimus—Anaemia—Docetaxel—head and neck cancer	0.000718	0.00136	CcSEcCtD
Everolimus—Syncope—Docetaxel—head and neck cancer	0.000697	0.00132	CcSEcCtD
Everolimus—Leukopenia—Docetaxel—head and neck cancer	0.000695	0.00131	CcSEcCtD
Everolimus—Body temperature increased—Fluorouracil—head and neck cancer	0.000694	0.00131	CcSEcCtD
Everolimus—Palpitations—Docetaxel—head and neck cancer	0.000687	0.0013	CcSEcCtD
Everolimus—Loss of consciousness—Docetaxel—head and neck cancer	0.000683	0.00129	CcSEcCtD
Everolimus—Cough—Docetaxel—head and neck cancer	0.000678	0.00128	CcSEcCtD
Everolimus—Convulsion—Docetaxel—head and neck cancer	0.000673	0.00127	CcSEcCtD
Everolimus—Hypertension—Docetaxel—head and neck cancer	0.000671	0.00127	CcSEcCtD
Everolimus—Arthralgia—Docetaxel—head and neck cancer	0.000661	0.00125	CcSEcCtD
Everolimus—Myalgia—Docetaxel—head and neck cancer	0.000661	0.00125	CcSEcCtD
Everolimus—Chest pain—Docetaxel—head and neck cancer	0.000661	0.00125	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000657	0.00124	CcSEcCtD
Everolimus—Hypersensitivity—Fluorouracil—head and neck cancer	0.000647	0.00122	CcSEcCtD
Everolimus—Dry mouth—Docetaxel—head and neck cancer	0.000647	0.00122	CcSEcCtD
Everolimus—Oedema—Docetaxel—head and neck cancer	0.000634	0.0012	CcSEcCtD
Everolimus—Infection—Docetaxel—head and neck cancer	0.00063	0.00119	CcSEcCtD
Everolimus—Shock—Docetaxel—head and neck cancer	0.000624	0.00118	CcSEcCtD
Everolimus—Nervous system disorder—Docetaxel—head and neck cancer	0.000622	0.00117	CcSEcCtD
Everolimus—Pruritus—Fluorouracil—head and neck cancer	0.000622	0.00117	CcSEcCtD
Everolimus—Thrombocytopenia—Docetaxel—head and neck cancer	0.000621	0.00117	CcSEcCtD
Everolimus—Tachycardia—Docetaxel—head and neck cancer	0.000619	0.00117	CcSEcCtD
Everolimus—Skin disorder—Docetaxel—head and neck cancer	0.000616	0.00116	CcSEcCtD
Everolimus—Anorexia—Docetaxel—head and neck cancer	0.000604	0.00114	CcSEcCtD
Everolimus—Diarrhoea—Fluorouracil—head and neck cancer	0.000601	0.00113	CcSEcCtD
Everolimus—Hypotension—Docetaxel—head and neck cancer	0.000593	0.00112	CcSEcCtD
Everolimus—Dizziness—Fluorouracil—head and neck cancer	0.000581	0.0011	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000578	0.00109	CcSEcCtD
Everolimus—Insomnia—Docetaxel—head and neck cancer	0.000574	0.00108	CcSEcCtD
Everolimus—Paraesthesia—Docetaxel—head and neck cancer	0.000569	0.00107	CcSEcCtD
Everolimus—Dyspnoea—Docetaxel—head and neck cancer	0.000565	0.00107	CcSEcCtD
Everolimus—Somnolence—Docetaxel—head and neck cancer	0.000564	0.00106	CcSEcCtD
Everolimus—Vomiting—Fluorouracil—head and neck cancer	0.000559	0.00105	CcSEcCtD
Everolimus—Dyspepsia—Docetaxel—head and neck cancer	0.000558	0.00105	CcSEcCtD
Everolimus—Rash—Fluorouracil—head and neck cancer	0.000554	0.00105	CcSEcCtD
Everolimus—Dermatitis—Fluorouracil—head and neck cancer	0.000553	0.00104	CcSEcCtD
Everolimus—Decreased appetite—Docetaxel—head and neck cancer	0.000551	0.00104	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—head and neck cancer	0.00055	0.00123	CbGpPWpGaD
Everolimus—Headache—Fluorouracil—head and neck cancer	0.00055	0.00104	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—MAPK3—head and neck cancer	0.00055	0.00123	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000547	0.00103	CcSEcCtD
Everolimus—Fatigue—Docetaxel—head and neck cancer	0.000547	0.00103	CcSEcCtD
Everolimus—Constipation—Docetaxel—head and neck cancer	0.000542	0.00102	CcSEcCtD
Everolimus—Pain—Docetaxel—head and neck cancer	0.000542	0.00102	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—MAPK3—head and neck cancer	0.000541	0.00121	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT6—head and neck cancer	0.000541	0.00121	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—PTEN—head and neck cancer	0.000537	0.0012	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—PTEN—head and neck cancer	0.000537	0.0012	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTEN—head and neck cancer	0.000537	0.0012	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—PIK3CA—head and neck cancer	0.000535	0.0012	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—head and neck cancer	0.000532	0.00119	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—head and neck cancer	0.000532	0.00119	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—PTEN—head and neck cancer	0.000532	0.00119	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—PIK3CA—head and neck cancer	0.000531	0.00119	CbGpPWpGaD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000529	0.00118	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—PTEN—head and neck cancer	0.000527	0.00118	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—MAPK3—head and neck cancer	0.000526	0.00118	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—PTEN—head and neck cancer	0.000525	0.00117	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—head and neck cancer	0.000524	0.00117	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—MAPK1—head and neck cancer	0.000523	0.00117	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—head and neck cancer	0.000523	0.00117	CbGpPWpGaD
Everolimus—Feeling abnormal—Docetaxel—head and neck cancer	0.000523	0.000986	CcSEcCtD
Everolimus—Nausea—Fluorouracil—head and neck cancer	0.000522	0.000985	CcSEcCtD
Everolimus—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000519	0.000979	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—MAPK3—head and neck cancer	0.000518	0.00116	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—STAT3—head and neck cancer	0.000518	0.00116	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	0.000517	0.00116	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—head and neck cancer	0.000515	0.00115	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—MAPK1—head and neck cancer	0.000515	0.00115	CbGpPWpGaD
Everolimus—Body temperature increased—Docetaxel—head and neck cancer	0.000501	0.000946	CcSEcCtD
Everolimus—Abdominal pain—Docetaxel—head and neck cancer	0.000501	0.000946	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—MAPK1—head and neck cancer	0.000501	0.00112	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—head and neck cancer	0.000501	0.00112	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—MAPK3—head and neck cancer	0.000497	0.00111	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—PTEN—head and neck cancer	0.000497	0.00111	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—AKT1—head and neck cancer	0.000496	0.00111	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MAPK1—head and neck cancer	0.000495	0.00111	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—head and neck cancer	0.000495	0.00111	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—MAPK3—head and neck cancer	0.000495	0.00111	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—HRAS—head and neck cancer	0.000495	0.00111	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—MAPK1—head and neck cancer	0.000493	0.0011	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—EGFR—head and neck cancer	0.000493	0.0011	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—MAPK3—head and neck cancer	0.000492	0.0011	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—head and neck cancer	0.000491	0.0011	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—MAPK3—head and neck cancer	0.00049	0.0011	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—MAPK3—head and neck cancer	0.000487	0.00109	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—AKT1—head and neck cancer	0.000484	0.00108	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—AKT1—head and neck cancer	0.000481	0.00108	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—STAT3—head and neck cancer	0.00048	0.00107	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—YAP1—head and neck cancer	0.000478	0.00107	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—head and neck cancer	0.000475	0.00106	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—MAPK1—head and neck cancer	0.000473	0.00106	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—MAPK1—head and neck cancer	0.000471	0.00105	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—EGFR—head and neck cancer	0.000471	0.00105	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT6—head and neck cancer	0.00047	0.00105	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—AKT1—head and neck cancer	0.00047	0.00105	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—head and neck cancer	0.00047	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—STAT3—head and neck cancer	0.000469	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—MAPK1—head and neck cancer	0.000468	0.00105	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—MAPK1—head and neck cancer	0.000468	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—head and neck cancer	0.000468	0.00105	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—head and neck cancer	0.000468	0.00105	CbGpPWpGaD
Everolimus—Hypersensitivity—Docetaxel—head and neck cancer	0.000467	0.000882	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—MAPK1—head and neck cancer	0.000466	0.00104	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—head and neck cancer	0.000466	0.00104	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—MAPK1—head and neck cancer	0.000464	0.00104	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—EGFR—head and neck cancer	0.000464	0.00104	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—head and neck cancer	0.000463	0.00104	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—MAPK3—head and neck cancer	0.000459	0.00103	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK3—head and neck cancer	0.000459	0.00103	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—MAPK3—head and neck cancer	0.000459	0.00103	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—head and neck cancer	0.000457	0.00102	CbGpPWpGaD
Everolimus—Asthenia—Docetaxel—head and neck cancer	0.000455	0.000859	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—MAPK3—head and neck cancer	0.000454	0.00102	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—PIK3CA—head and neck cancer	0.000454	0.00102	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—MAPK3—head and neck cancer	0.00045	0.00101	CbGpPWpGaD
Everolimus—Pruritus—Docetaxel—head and neck cancer	0.000449	0.000847	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—MAPK3—head and neck cancer	0.000448	0.001	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—AKT1—head and neck cancer	0.000437	0.000977	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—MAPK1—head and neck cancer	0.000436	0.000977	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—MAPK1—head and neck cancer	0.000436	0.000977	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK1—head and neck cancer	0.000436	0.000977	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—head and neck cancer	0.000436	0.000976	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—head and neck cancer	0.000436	0.000976	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—EGFR—head and neck cancer	0.000436	0.000976	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—PIK3CA—head and neck cancer	0.000435	0.000973	CbGpPWpGaD
Everolimus—Diarrhoea—Docetaxel—head and neck cancer	0.000434	0.000819	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—MAPK1—head and neck cancer	0.000432	0.000968	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—EGFR—head and neck cancer	0.000432	0.000968	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—MAPK1—head and neck cancer	0.000429	0.000959	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—head and neck cancer	0.000428	0.000959	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—PIK3CA—head and neck cancer	0.000428	0.000957	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—MAPK1—head and neck cancer	0.000427	0.000955	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—head and neck cancer	0.000427	0.000955	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—head and neck cancer	0.000425	0.000952	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—head and neck cancer	0.00042	0.00094	CbGpPWpGaD
Everolimus—Dizziness—Docetaxel—head and neck cancer	0.000419	0.000792	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—head and neck cancer	0.000416	0.000931	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—HRAS—head and neck cancer	0.000413	0.000925	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—PIK3CA—head and neck cancer	0.00041	0.000919	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—PIK3CA—head and neck cancer	0.000408	0.000914	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—PIK3CA—head and neck cancer	0.000406	0.00091	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MAPK3—head and neck cancer	0.000406	0.000909	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—PIK3CA—head and neck cancer	0.000404	0.000905	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—head and neck cancer	0.000404	0.000904	CbGpPWpGaD
Everolimus—Vomiting—Docetaxel—head and neck cancer	0.000403	0.000761	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—PIK3CA—head and neck cancer	0.000402	0.000901	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—head and neck cancer	0.000402	0.0009	CbGpPWpGaD
Everolimus—Rash—Docetaxel—head and neck cancer	0.0004	0.000755	CcSEcCtD
Everolimus—Dermatitis—Docetaxel—head and neck cancer	0.000399	0.000754	CcSEcCtD
Everolimus—Headache—Docetaxel—head and neck cancer	0.000397	0.00075	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—head and neck cancer	0.000397	0.000888	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—HRAS—head and neck cancer	0.000396	0.000886	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MAPK1—head and neck cancer	0.000386	0.000865	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—head and neck cancer	0.000386	0.000865	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KISS1—head and neck cancer	0.00038	0.000851	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—HRAS—head and neck cancer	0.00038	0.00085	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PIK3CA—head and neck cancer	0.000379	0.000847	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—PIK3CA—head and neck cancer	0.000379	0.000847	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—PIK3CA—head and neck cancer	0.000379	0.000847	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—HRAS—head and neck cancer	0.000378	0.000846	CbGpPWpGaD
Everolimus—Nausea—Docetaxel—head and neck cancer	0.000377	0.000711	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—head and neck cancer	0.000376	0.000842	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—HRAS—head and neck cancer	0.000376	0.000842	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—PIK3CA—head and neck cancer	0.000375	0.00084	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—HRAS—head and neck cancer	0.000374	0.000837	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—HRAS—head and neck cancer	0.000372	0.000833	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—PIK3CA—head and neck cancer	0.000372	0.000832	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—AKT1—head and neck cancer	0.000371	0.00083	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—PIK3CA—head and neck cancer	0.00037	0.000829	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—head and neck cancer	0.000367	0.000821	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PTEN—head and neck cancer	0.000366	0.000818	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—AKT1—head and neck cancer	0.000365	0.000817	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BCL2L1—head and neck cancer	0.000359	0.000803	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—head and neck cancer	0.000355	0.000795	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VEGFA—head and neck cancer	0.000352	0.000788	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—head and neck cancer	0.000351	0.000786	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—PIK3CA—head and neck cancer	0.00035	0.000784	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—head and neck cancer	0.00035	0.000784	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—head and neck cancer	0.00035	0.000784	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—head and neck cancer	0.00035	0.000784	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—AKT1—head and neck cancer	0.000349	0.000782	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—STAT3—head and neck cancer	0.000349	0.00078	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—head and neck cancer	0.000347	0.000777	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—head and neck cancer	0.000344	0.00077	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—head and neck cancer	0.000343	0.000767	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—head and neck cancer	0.000335	0.000751	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—head and neck cancer	0.000335	0.000751	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—AKT1—head and neck cancer	0.000334	0.000747	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—MAPK3—head and neck cancer	0.000333	0.000745	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—AKT1—head and neck cancer	0.000332	0.000743	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—head and neck cancer	0.000332	0.000743	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—AKT1—head and neck cancer	0.00033	0.000739	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—AKT1—head and neck cancer	0.000329	0.000736	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—head and neck cancer	0.000327	0.000732	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—HRAS—head and neck cancer	0.000324	0.000726	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—head and neck cancer	0.000324	0.000725	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—MAPK1—head and neck cancer	0.000317	0.000709	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GRP—head and neck cancer	0.000313	0.000701	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK3—head and neck cancer	0.000312	0.000699	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	0.00031	0.000694	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—head and neck cancer	0.000309	0.000692	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	0.000309	0.000692	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—head and neck cancer	0.000309	0.000692	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOTCH1—head and neck cancer	0.000308	0.000689	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—head and neck cancer	0.000307	0.000686	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT6—head and neck cancer	0.000304	0.000681	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—head and neck cancer	0.000304	0.00068	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—head and neck cancer	0.000302	0.000677	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK1—head and neck cancer	0.000297	0.000665	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—head and neck cancer	0.000297	0.000665	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000296	0.000663	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CASP8—head and neck cancer	0.000293	0.000657	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000292	0.000654	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—AKT1—head and neck cancer	0.000286	0.000641	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.000281	0.000629	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDH1—head and neck cancer	0.000278	0.000623	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000277	0.00062	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	0.000274	0.000613	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—YAP1—head and neck cancer	0.000269	0.000602	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—head and neck cancer	0.000266	0.000595	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PIK3CA—head and neck cancer	0.000258	0.000577	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BCL2—head and neck cancer	0.000252	0.000563	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UROD—head and neck cancer	0.000247	0.000553	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HRAS—head and neck cancer	0.000239	0.000534	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—head and neck cancer	0.000229	0.000512	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH1—head and neck cancer	0.000216	0.000483	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—head and neck cancer	0.000211	0.000472	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2L1—head and neck cancer	0.000209	0.000468	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTEN—head and neck cancer	0.000209	0.000467	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTEN—head and neck cancer	0.0002	0.000448	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—head and neck cancer	0.000199	0.000446	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—head and neck cancer	0.000178	0.000399	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK3—head and neck cancer	0.000178	0.000399	CbGpPWpGaD
Everolimus—MTOR—Disease—NOTCH1—head and neck cancer	0.000173	0.000388	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP8—head and neck cancer	0.000171	0.000382	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK3—head and neck cancer	0.00017	0.000381	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK1—head and neck cancer	0.00017	0.000379	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—head and neck cancer	0.000169	0.000379	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—head and neck cancer	0.000169	0.000378	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—head and neck cancer	0.000163	0.000364	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK1—head and neck cancer	0.000162	0.000363	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—head and neck cancer	0.000162	0.000363	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—head and neck cancer	0.000148	0.000332	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—head and neck cancer	0.000147	0.000329	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—head and neck cancer	0.000147	0.000328	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—head and neck cancer	0.000145	0.000324	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—head and neck cancer	0.000141	0.000316	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—head and neck cancer	0.000141	0.000315	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—head and neck cancer	0.00014	0.000313	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—head and neck cancer	0.000136	0.000305	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—head and neck cancer	0.000131	0.000293	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—head and neck cancer	0.00013	0.000291	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—head and neck cancer	0.000129	0.000289	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—head and neck cancer	0.000129	0.000288	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—head and neck cancer	0.000126	0.000282	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—head and neck cancer	0.000125	0.000279	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—head and neck cancer	0.000121	0.000272	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH1—head and neck cancer	0.000121	0.000271	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—head and neck cancer	0.00012	0.000269	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK3—head and neck cancer	0.000119	0.000267	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—head and neck cancer	0.000115	0.000258	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—head and neck cancer	0.000115	0.000257	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK1—head and neck cancer	0.000114	0.000254	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—head and neck cancer	0.000113	0.000254	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—head and neck cancer	0.000112	0.000251	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—head and neck cancer	0.000109	0.000243	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK3—head and neck cancer	0.000104	0.000232	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NAT2—head and neck cancer	0.000103	0.00023	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—head and neck cancer	0.0001	0.000224	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK1—head and neck cancer	9.87e-05	0.000221	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—head and neck cancer	9.87e-05	0.000221	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—head and neck cancer	9.85e-05	0.00022	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK3—head and neck cancer	9.58e-05	0.000214	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—head and neck cancer	9.53e-05	0.000213	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK1—head and neck cancer	9.12e-05	0.000204	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—head and neck cancer	9.11e-05	0.000204	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—head and neck cancer	9.11e-05	0.000204	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DPYD—head and neck cancer	8.99e-05	0.000201	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—head and neck cancer	8.57e-05	0.000192	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—YAP1—head and neck cancer	8.53e-05	0.000191	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—head and neck cancer	8.34e-05	0.000187	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—head and neck cancer	8.13e-05	0.000182	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—head and neck cancer	8.05e-05	0.00018	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—head and neck cancer	7.93e-05	0.000177	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—head and neck cancer	7.91e-05	0.000177	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—head and neck cancer	7.85e-05	0.000176	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—head and neck cancer	7.32e-05	0.000164	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—head and neck cancer	7.09e-05	0.000159	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—head and neck cancer	7.02e-05	0.000157	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—head and neck cancer	7e-05	0.000157	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK3—head and neck cancer	6.71e-05	0.00015	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—head and neck cancer	6.46e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK1—head and neck cancer	6.38e-05	0.000143	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—head and neck cancer	6.38e-05	0.000143	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—head and neck cancer	5.54e-05	0.000124	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—head and neck cancer	5.36e-05	0.00012	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMS—head and neck cancer	5.12e-05	0.000115	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—head and neck cancer	5.12e-05	0.000115	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—head and neck cancer	5.07e-05	0.000113	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX1—head and neck cancer	4.85e-05	0.000109	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1A1—head and neck cancer	4.8e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—head and neck cancer	4.53e-05	0.000101	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.86e-05	6.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—head and neck cancer	2.49e-05	5.58e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.76e-05	3.93e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—head and neck cancer	1.44e-05	3.21e-05	CbGpPWpGaD
